Improving Outcomes in Ocular Melanoma: A Multidisciplinary Perspective – A/Prof Max Conway

Improving Outcomes in Ocular Melanoma: A Multidisciplinary Perspective – A/Prof Max Conway

Publication date: Jun 10, 2019

Associate Professor Max Conway presents on using a multidisciplinary approach when treating patients with ocular melanoma at the 1st Australasian Ocular Melanoma Summit, held at the Garvan Institute of Medical Research in Sydney on May 3rd-4th, 2019.

The Australasian Ocular Melanoma Alliance (AOMA) presents the 1st Australasian Ocular Melanoma Summit. The AOMA group was founded in late 2017 by Melanoma and Skin Cancer Trials Ltd to support clinicians and researchers from all disciplines to develop, seek funding for, and collaborate on clinical trials in ocular melanoma.

Follow us at;

Australasian Ocular Melanoma Alliance – @AOMA_MASC

Melanoma and Skin Cancer Trials – @MASC_Trials

For more information contact us at admin@masc.org.au

The event was sponsored/supported by;

Melanoma and Skin Cancer Trials Limited, The Garvan Institute of Medical Research and Kinghorn Cancer Centre, Melanoma Institute Australia, The Save Sight Institute, SydPath and Cancer Australia.

Concepts Keywords
Anxiety Advanced disease
Australia Conduct title melanoma
Bean Disease minister disease
Bono Similar detainees melanoma
Breast Treatments ocular melanoma
Clinical Trials Prognosis Tumors
Condom Restrictions melanoma
Eggs Survival cancers
European Commission Photodynamic therapy
Genetic Mutation Radiotherapy
Gentile Surgery
Holistic Radiation
Integral Medicine
IQ Melanoma
Island RTT
Kinghorn Medical physics
Laser Health
Liverpool Clinical medicine
Manager Cancer
MDT Uveal melanoma
Melanoma Radiation therapy
Melanomas Proton therapy
Melon DecisionDx-UM
Minister J. William Harbour
Multi Disciplinary Radiation
Mutation Laser
Nanoparticle Loudly detailed protocol
Northern Beaches
Ocular Melanoma
Ocular Surgery
Oncologist
Ophthalmologist
Orbit
Paradigm Shift
Pathologist
Pathology
Pet Scan
Photodynamic Therapy
Primary Care Physician
Primary Tumor
Pro Bono
Prognosis
Protocol
Proton Therapy
Quorum
Radiation Oncologist
Radiotherapy
Remission
Resection
Social Worker
Supportive Care
Surgeon
Surveillance
Sydney
Sydney Hospital
Targeted Therapies
Targeted Treatments
The Australasian
Topical
Vill
Wales

Semantics

Type Source Name
disease DOID Cancer
disease MESH Cancer
disease DOID Skin Cancer
disease MESH Skin Cancer
pathway BSID Melanoma
disease DOID Melanoma
disease MESH Melanoma
gene UNIPROT ARID1A
gene UNIPROT MAX
gene UNIPROT WDFY2
disease DOID Ocular Melanoma

Similar

Original Article

Leave a Comment

Your email address will not be published. Required fields are marked *